Journal
PSYCHIATRY RESEARCH
Volume 175, Issue 1-2, Pages 179-180Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2009.01.025
Keywords
Schizophrenia; Sensory gating; Varenicline
Categories
Funding
- [VISN19/MIRECC]
- [RO1 MH50787-08.]
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050787] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating. Published by Elsevier Ireland Ltd
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available